Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
Infection because of herpes simplex virus (HSV) that is resistant to acyclovir (ACV) poses treatment challenges in hematopoietic cell transplant (HCT) patients. We present a series of patients with ACV-resistant HSV following HCT who were successfully treated with continuous infusion high-dose ACV after failing standard treatment regimens for ACV-resistant HSV.
Kim
Janet H
JH
Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Schaenman
Joanna M
JM
Ho
Dora Y
DY
Brown
Janice M Y
JM
D000212:Acyclovir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D024921:Drug Resistance, Multiple, Viral; D024882:Drug Resistance, Viral; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018139:Simplexvirus / Q000187:drug effects* / Q000302:isolation & purification; D016896:Treatment Outcome
D000998:Antiviral Agents; D000212:Acyclovir